Trials / Completed
CompletedNCT01003691
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A PHASE 1, DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING DOSAGES OF RN6G (PF-04382923) IN SUBJECTS WITH ADVANCED DRY, AGE-RELATED MACULAR DEGENERATION (AMD) INCLUDING GEOGRAPHIC ATROPHY
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.
Conditions
- Age-Related Maculopathy
- Age-Related Maculopathies
- Eye Diseases
- Retinal Degeneration
- Macular Degeneration
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RN6G | Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg |
| BIOLOGICAL | Placebo | Intravenous, multiple dose with experimental dose |
Timeline
- Start date
- 2010-08-05
- Primary completion
- 2013-03-05
- Completion
- 2013-04-19
- First posted
- 2009-10-29
- Last updated
- 2022-05-12
- Results posted
- 2022-05-12
Locations
24 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01003691. Inclusion in this directory is not an endorsement.